Neuraxpharm launches first product in Japan
Launch of Buccolam® – market leading product for emergency treatment of children with epilepsy suffering from prolonged acute convulsive seizures – following recent acquisition from Takeda
First buccal midazolam to receive approval in Japan, world’s second largest central nervous system market [1]
Düsseldorf and Barcelona, January, 12, 2021 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces the launch in Japan of the recently acquired prescription brand Buccolam® (oromucosal midazolam) following its approval as the first buccally administered formulation for the treatment of status epilepticus (SE) in the country.
